Melanoma biomarkers: Current status and vision for the future

Rhoda M. Alani, Allison R. Larson, Eliz Konat

Research output: Contribution to journalArticle

Abstract

Melanoma is the leading cause of death from skin cancer in industrialized countries. Clinical and histological variables such as primary tumor invasion, ulceration, and lymph node status might fail to identify early-stage disease that will eventually progress. Tumor biomarkers might help to identify patients with early-stage melanoma who are likely to develop advanced disease and would benefit from additional therapies. These biomarkers offer the possibility of improved tumor staging through the molecular detection of microscopic lymph node metastases that are not visible on routine histological examination. We focus on biomarkers localized to the tumor tissue and those of prognostic value. We give an overview of the melanoma biomarkers that are most helpful for prediction of patients' outcomes, and discuss the primary melanoma biomarkers that have been shown to be of prognostic significance independent of primary tumor thickness and other common clinical prognostic indicators. Although such tumor-associated biomarkers are thought to have the greatest potential, a lack of reliable data makes their true clinical utility difficult to determine. We conclude that several biomarkers show promise in early studies; however, additional large-scale studies are warranted. We suggest cautious optimism for the field of melanoma biomarkers, which we expect to be translated into clinical practice over the next few years.

Original languageEnglish (US)
Pages (from-to)105-117
Number of pages13
JournalNature Reviews Clinical Oncology
Volume6
Issue number2
StatePublished - Feb 2009

Fingerprint

Melanoma
Biomarkers
Tumor Biomarkers
Lymph Nodes
Neoplasms
Neoplasm Staging
Skin Neoplasms
Developed Countries
Cause of Death
Neoplasm Metastasis
Therapeutics

Keywords

  • Biomarker
  • Breslow thickness
  • Histology
  • Melanoma
  • Prognosis

ASJC Scopus subject areas

  • Oncology

Cite this

Alani, R. M., Larson, A. R., & Konat, E. (2009). Melanoma biomarkers: Current status and vision for the future. Nature Reviews Clinical Oncology, 6(2), 105-117.

Melanoma biomarkers : Current status and vision for the future. / Alani, Rhoda M.; Larson, Allison R.; Konat, Eliz.

In: Nature Reviews Clinical Oncology, Vol. 6, No. 2, 02.2009, p. 105-117.

Research output: Contribution to journalArticle

Alani, RM, Larson, AR & Konat, E 2009, 'Melanoma biomarkers: Current status and vision for the future', Nature Reviews Clinical Oncology, vol. 6, no. 2, pp. 105-117.
Alani, Rhoda M. ; Larson, Allison R. ; Konat, Eliz. / Melanoma biomarkers : Current status and vision for the future. In: Nature Reviews Clinical Oncology. 2009 ; Vol. 6, No. 2. pp. 105-117.
@article{cf8f6d5d2d47458b950eb238abdb83a9,
title = "Melanoma biomarkers: Current status and vision for the future",
abstract = "Melanoma is the leading cause of death from skin cancer in industrialized countries. Clinical and histological variables such as primary tumor invasion, ulceration, and lymph node status might fail to identify early-stage disease that will eventually progress. Tumor biomarkers might help to identify patients with early-stage melanoma who are likely to develop advanced disease and would benefit from additional therapies. These biomarkers offer the possibility of improved tumor staging through the molecular detection of microscopic lymph node metastases that are not visible on routine histological examination. We focus on biomarkers localized to the tumor tissue and those of prognostic value. We give an overview of the melanoma biomarkers that are most helpful for prediction of patients' outcomes, and discuss the primary melanoma biomarkers that have been shown to be of prognostic significance independent of primary tumor thickness and other common clinical prognostic indicators. Although such tumor-associated biomarkers are thought to have the greatest potential, a lack of reliable data makes their true clinical utility difficult to determine. We conclude that several biomarkers show promise in early studies; however, additional large-scale studies are warranted. We suggest cautious optimism for the field of melanoma biomarkers, which we expect to be translated into clinical practice over the next few years.",
keywords = "Biomarker, Breslow thickness, Histology, Melanoma, Prognosis",
author = "Alani, {Rhoda M.} and Larson, {Allison R.} and Eliz Konat",
year = "2009",
month = "2",
language = "English (US)",
volume = "6",
pages = "105--117",
journal = "Nature Clinical Practice Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Melanoma biomarkers

T2 - Current status and vision for the future

AU - Alani, Rhoda M.

AU - Larson, Allison R.

AU - Konat, Eliz

PY - 2009/2

Y1 - 2009/2

N2 - Melanoma is the leading cause of death from skin cancer in industrialized countries. Clinical and histological variables such as primary tumor invasion, ulceration, and lymph node status might fail to identify early-stage disease that will eventually progress. Tumor biomarkers might help to identify patients with early-stage melanoma who are likely to develop advanced disease and would benefit from additional therapies. These biomarkers offer the possibility of improved tumor staging through the molecular detection of microscopic lymph node metastases that are not visible on routine histological examination. We focus on biomarkers localized to the tumor tissue and those of prognostic value. We give an overview of the melanoma biomarkers that are most helpful for prediction of patients' outcomes, and discuss the primary melanoma biomarkers that have been shown to be of prognostic significance independent of primary tumor thickness and other common clinical prognostic indicators. Although such tumor-associated biomarkers are thought to have the greatest potential, a lack of reliable data makes their true clinical utility difficult to determine. We conclude that several biomarkers show promise in early studies; however, additional large-scale studies are warranted. We suggest cautious optimism for the field of melanoma biomarkers, which we expect to be translated into clinical practice over the next few years.

AB - Melanoma is the leading cause of death from skin cancer in industrialized countries. Clinical and histological variables such as primary tumor invasion, ulceration, and lymph node status might fail to identify early-stage disease that will eventually progress. Tumor biomarkers might help to identify patients with early-stage melanoma who are likely to develop advanced disease and would benefit from additional therapies. These biomarkers offer the possibility of improved tumor staging through the molecular detection of microscopic lymph node metastases that are not visible on routine histological examination. We focus on biomarkers localized to the tumor tissue and those of prognostic value. We give an overview of the melanoma biomarkers that are most helpful for prediction of patients' outcomes, and discuss the primary melanoma biomarkers that have been shown to be of prognostic significance independent of primary tumor thickness and other common clinical prognostic indicators. Although such tumor-associated biomarkers are thought to have the greatest potential, a lack of reliable data makes their true clinical utility difficult to determine. We conclude that several biomarkers show promise in early studies; however, additional large-scale studies are warranted. We suggest cautious optimism for the field of melanoma biomarkers, which we expect to be translated into clinical practice over the next few years.

KW - Biomarker

KW - Breslow thickness

KW - Histology

KW - Melanoma

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=73949120017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73949120017&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:73949120017

VL - 6

SP - 105

EP - 117

JO - Nature Clinical Practice Oncology

JF - Nature Clinical Practice Oncology

SN - 1759-4774

IS - 2

ER -